Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma

BACKGROUND: Ameloblastoma imposes significant morbidity and high‐recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. CASE: We describe a case of a 40‐year‐old male with multiply recurrent, locally inva...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawson‐Michod, Katherine A., Le, Christopher H., Tranesh, Ghassan, Thomas, Penelope C., Bauman, Julie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575481/
https://www.ncbi.nlm.nih.gov/pubmed/35761436
http://dx.doi.org/10.1002/cnr2.1656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575481/
https://www.ncbi.nlm.nih.gov/pubmed/35761436
http://dx.doi.org/10.1002/cnr2.1656

Ejemplares similares